Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Abbas Alipour 1 Article
Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis
Sohrab Iranpour, Ali Hosseinzadeh, Abbas Alipour
Epidemiol Health. 2019;41:e2019011.   Published online March 31, 2019
DOI: https://doi.org/10.4178/epih.e2019011
  • 15,703 View
  • 352 Download
  • 12 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary Material
Abstract
Cutaneous leishmaniasis (CL) is most common form of leishmaniasis and is characterized by ulcerative skin lesions. The objective of this study was to conduct a systematic review and meta-analysis of clinical trials that compared the efficacy of miltefosine and glucantime for the treatment of CL. We searched the following databases: Cochrane, PubMed, Embase, Scopus, Web of Science, ProQuest, Cochrane Central Register of Controlled Trials, International Clinical Trials Registry Platform search portal of World Health Organization, Sid, Irandoc, Magiran, and clinicaltrials.gov. We used keywords including “miltefosine,” “glucantime,” and “Leishmania.” The quality of studies was assessed using the Cochrane risk of bias tool. A random-effects model was employed for the analysis. We assessed heterogeneity by the chi-square test and the I2 index statistic. When heterogeneity was present, meta-regression analyses were performed. The Egger method was used to assess publication bias; when it was significant, the trim-and-fill method was used to test and adjust for publication bias. A total of 1,570 reports were identified, of which 10 studies were included in the meta-analysis. In the meta-analysis, there was no significant difference between the efficacy of miltefosine and glucantime; however, subgroup analysis showed that, regarding parasite species other than Leishmania braziliensis, miltefosine was significantly superior to glucantime (intention to treat; relative risk, 1.15; 95% confidence interval, 1.01 to 1.32). In the meta-regression, only the glucantime injection type was significant at the p=0.1 level. The Egger test found statistically significant publication bias; however, including the 3 missing studies in the trim-and-fill analysis did not change the results. This meta-analysis found that miltefosine seems to be more effective than glucantime, at least in species other than L. braziliensis, for treating CL.
Summary

Citations

Citations to this article as recorded by  
  • Successful Treatment of Rapidly Evolving Cutaneous Leishmaniasis With Amphotericin B and Miltefosine in an Immigrant From Venezuela
    Danielle M Mullis, Evan Shegog, Lucy Studemeister, Michael Hwang
    Open Forum Infectious Diseases.2024;[Epub]     CrossRef
  • Microwave-Assisted Semisynthesis and Leishmanicidal Activity of Some Phenolic Constituents from Lichens
    Grover Castañeta, Rodrigo Villagomez, Efrain Salamanca, Pamela Canaviri-Paz, José A. Bravo, José L. Vila, Daniela Bárcenas-Pérez, José Cheel, Beatriz Sepúlveda, Alberto Giménez, Carlos Areche
    Separations.2023; 10(10): 524.     CrossRef
  • Mesenchymal Stromal Cell‐derived Extracellular Vesicles in Preclinical Animal Models of Tumor Growth: Systematic Review and Meta‐analysis
    Adrian J.M. Bailey, Alvin Tieu, Manika Gupta, Mitchell Slobodian, Risa Shorr, Tim Ramsay, Rosendo A. Rodriguez, Dean A. Fergusson, Manoj M. Lalu, David S. Allan
    Stem Cell Reviews and Reports.2022; 18(3): 993.     CrossRef
  • Tratamiento de leishmaniasis cutánea infantil con miltefosina
    P.J. Barba, D. Morgado-Carrasco, A. Quera
    Actas Dermo-Sifiliográficas.2022; 113(8): 827.     CrossRef
  • [Translated article] Miltefosine to Treat Childhood Cutaneous Leishmaniasis
    P.J. Barba, D. Morgado-Carrasco, A. Quera
    Actas Dermo-Sifiliográficas.2022; 113(8): T827.     CrossRef
  • Leishmaniasis cutánea y mucocutánea
    I. Abadías-Granado, A. Diago, P.A. Cerro, A.M. Palma-Ruiz, Y. Gilaberte
    Actas Dermo-Sifiliográficas.2021; 112(7): 601.     CrossRef
  • Comparative assessment of interventions for treating cutaneous leishmaniasis: A network meta-analysis of randomized clinical trials.
    Kannan Sridharan, Gowri Sivaramakrishnan
    Acta Tropica.2021; 220: 105944.     CrossRef
  • Cutaneous and Mucocutaneous Leishmaniasis
    I. Abadías-Granado, A. Diago, P.A. Cerro, A.M. Palma-Ruiz, Y. Gilaberte
    Actas Dermo-Sifiliográficas (English Edition).2021; 112(7): 601.     CrossRef
  • Lanthanide(III) Based Complexes Containing 5,7‐Dimethyl‐1,2,4‐triazolo[1,5‐a]pyrimidine as Long‐Lived Photoluminescent Antiparasitic Agents
    Ginés M. Esteban‐Parra, Inmaculada Moscoso, Javier Cepeda, Jose A. García, Manuel Sánchez‐Moreno, Antonio Rodríguez‐Diéguez, Miguel Quirós
    European Journal of Inorganic Chemistry.2020; 2020(3): 308.     CrossRef
  • Intraspecific Genomic Divergence and Minor Structural Variations in Leishmania (Viannia) panamensis
    Luz H. Patino, Marina Muñoz, Carlos Muskus, Claudia Méndez, Juan David Ramírez
    Genes.2020; 11(3): 252.     CrossRef
  • Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis
    Isabela A. G. Pereira, Débora V. C. Mendonça, Grasiele S. V. Tavares, Daniela P. Lage, Fernanda F. Ramos, João A. Oliveira‐da‐Silva, Luciana M. R. Antinarelli, Amanda S. Machado, Lívia M. Carvalho, Ana Maria R. S. Carvalho, Iorrana V. Salustiano, Thiago A
    Parasite Immunology.2020;[Epub]     CrossRef

Epidemiol Health : Epidemiology and Health
TOP